6CM
LYRA

683 Capital Management’s LYRA THERAPEUTICS INC LYRA Stock Holding History

683 Capital Management’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,397
Closed -$366K – 208
2023
Q4 		$366K Buy
+1,397
New +$253K 0.03% 103

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

683 Capital Management's LYRA Position: Q1 2024 in Review

683 Capital Management sold out of LYRA THERAPEUTICS INC (LYRA) in Q1 2024, closing a stake of 1,397 shares — an estimated $366K sold.

683 Capital Management first reported a position in LYRA in Q4 2023 and held it in 1 quarter. The position peaked at $366K in Q4 2023. 78 funds tracked by Wall St. Rank hold LYRA as of Q1 2024.

  • 683 Capital Management reported no remaining LYRA THERAPEUTICS INC position as of Q1 2024 after selling out during the quarter.
  • 683 Capital Management sold 1,397 LYRA THERAPEUTICS INC shares in Q1 2024, an estimated $366K.
  • 683 Capital Management first reported a position in LYRA THERAPEUTICS INC in Q4 2023 and held it in 1 quarter.
  • 683 Capital Management's LYRA THERAPEUTICS INC position peaked at $366K in Q4 2023.
  • 78 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.